Physician profile
Steve Hu
NPI 1568880508
$2,498.96
in general payments reported to CMS, 2019-2025
15 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $41.76 · 2021: $562 · 2022: $1,622 · 2023: $12.74 · 2024: $91.24 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pylant Medical | $1,200.00 | 2022 | |
| Boston Scientific Corporation | $548.16 | 2021-2022 | |
| Abbvie INC. | $454.49 | 2020-2025 | |
| Gilead Sciences, INC. | $47.04 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $46.19 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $37.19 | 2020-2021 | |
| Biocon Biologics INC | $28.98 | 2025 | Yesintek |
| Phathom Pharmaceuticals, INC. | $28.76 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $20.72 | 2022 | |
| Apollo Endosurgery US INC | $17.20 | 2022 | |
| Janssen Biotech, INC. | $15.59 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $14.69 | 2024 | Andexxa |
| Celltrion USA INC. | $13.48 | 2025 | Vegzelma |
| Qol Medical, LLC | $13.36 | 2022 | |
| Medtronic, INC. | $13.11 | 2024 | Gi Genius |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.